BioSpace News Archive

Deals

Rapport Therapeutics and Telix Pharma File IPOs as Number of Biotechs Going Public Slows

Neuroscience-focused Rapport Therapeutics and radiopharma developer Telix Pharma announced their respective plans Friday for initial public offerings on the Nasdaq for undisclosed dollar amounts.

May 20, 2024
·
2 min read
·
Kate Goodwin
Drug Development

Gilead Touts Phase III Results for Liver Disease Drug Ahead of PDUFA Date

Seladelpar, which Gilead acquired when it bought CymaBay in February for $4.3 billion, showed positive results for reducing pruritus in primary biliary cholangitis patients and reducing inflammation.

May 20, 2024
·
2 min read
·
Tyler Patchen
Drug Development

30 Years After Genetic Discovery, Huntington’s Patients Still Waiting

Following a series of clinical failures, optimism builds for the first disease-modifying treatment.

May 20, 2024
·
6 min read
·
Heather McKenzie
Can AI Help Biopharma Companies Go Green?

The insights AI affords can potentially boost sustainability, but it’s unclear whether these gains outweigh the technology’s environmental cost.

May 20, 2024
·
6 min read
·
Sanjukta Mondal
Drug Development

Despite Progress, ADCs Still Stalled in Non-Small Cell Lung Cancer

Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients with lung cancer, experts told BioSpace.

May 20, 2024
·
5 min read
·
Mollie Barnes